Atopic Dermatitis: Targeting Underlying Inflammatory Pathways with Systemic Therapy THE THRIVE INITIATIVE

Target Audience

This activity is intended for allergists, immunologists, and other healthcare professionals involved in the management of patients with atopic dermatitis.

Learning Objectives

  • Apply up-to-date guidance on the initiation and use of systemic immunosuppressants and immunomodulators in patients with atopic dermatitis during the COVID-19 pandemic
  • Assess the severity of atopic dermatitis and select appropriate treatment options for patients who require intensified therapy
  • Review the mechanism of action, efficacy and safety of systemic treatments for atopic dermatitis in pediatric and adult patients

Disclosure Of Financial Relationships

Dr. Donald Leung, has done contracted research for Sanofi Genzyme. He has also received consulting fees from Boehringer-Ingelheim, Evommune, Genentech, Incyte Corp and Leo Pharma.

Dr. Peter Lio, has served on the advisory board for the National Eczema Association, Modernizing Medicine, Johnson & Johnson, DermTap Inc., IntraDerm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, DermVeda, GPower Inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Verrica Pharmaceuticals Inc., Arbonne, Yobee Care Inc., and Bodewell. Dr. Lio is a stockholder in Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He has been a speaker for Pierre Fabre Dermatologie, Regeneron, Pfizer, and La Roche-Posay. He has been an investigator for La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), AOBiome LLC, Regeneron, AbbVie, and National Eczema Association. He has been a consultant for Exeltis, Therplex, Odeza LLC, L’Oreal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Eli Lilly and Co., Unilever, Dermira, TopMD, Amyris Inc., Leo Pharma, and Burt’s Bees.

Staff, Planners and Managers

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Diana Tommasi, PharmD, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Amanda Jenkins, Associate Program Manager for Med Learning Group has nothing to disclose.

Method Of Participation

  1. Participate in the live activity.
  2. Complete and submit the evaluation form to Med Learning Group.

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.

Provided by Med Learning Group

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Release date: November 4, 2021
Expiration date: November 4, 2022
Estimated time to completion: 1.5 hours